St. Anthony Greek Orthodox Church Community Center Ribbon Cutting

first_imgFaith & Religion News St. Anthony Greek Orthodox Church Community Center Ribbon Cutting Article and Photos courtesy of St. Anthony Greek Orthodox Church Published on Friday, August 17, 2012 | 1:34 pm Get our daily Pasadena newspaper in your email box. Free.Get all the latest Pasadena news, more than 10 fresh stories daily, 7 days a week at 7 a.m. Home of the Week: Unique Pasadena Home Located on Madeline Drive, Pasadena Community News Subscribe Top of the News Pasadena’s ‘626 Day’ Aims to Celebrate City, Boost Local Economy Name (required)  Mail (required) (not be published)  Website  HerbeautyThe Most Heartwarming Moments Between Father And DaughterHerbeautyHerbeautyHerbeautyIs It Bad To Give Your Boyfriend An Ultimatum?HerbeautyHerbeautyHerbeautyInstall These Measures To Keep Your Household Safe From Covid19HerbeautyHerbeautyHerbeautyA Mental Health Chatbot Which Helps People With DepressionHerbeautyHerbeautyHerbeautyThis Trend Looks Kind Of Cool!HerbeautyHerbeautyHerbeautyHere Is What Scientists Say Will Happen When You Eat AvocadosHerbeautyHerbeauty 5 recommended0 commentsShareShareTweetSharePin it St. Anthony Greek Orthodox Church recently opened their new Community Church with a ribbon cutting with the blessing from Metropolitan Gerasimos and a dinner and dance. There were approximately 300 people in attendance.The church specially the Parish Council president Ted Vavoulis expresses their sincerest gratitude for those who contributed to build the Community Church through donations. Much sacrifice and tireless hard work by many has transpired. The Parish Council president would like to publicly thank three people without whom the project would not have been possible. The text below was an excerpt President Ted Vavoulis’ message in contained in the newsletter:“John Buzas, as chairman of the building committee, put his heart and soul into the community center. He worked tirelessly and without complaint. The community owes him a great debt of gratitude for his unwavering service.The second person is Randy Soewers. Randy was the chairman of the design committee. Randy’s knowledge of design and how to get a project of such size from the starting point to the ending point was essential to its success. He worked diligently on the details of the project. He was the consummate taskmaster-making sure everyone was doing what they were supposed to be doing. The community is grateful for his service.The third person is the beloved Father Peter who provided guidance, devotion, love and support throughout the entire project. It was not easy for Father Peter to arrive at St. Anthony after the passing of the long-time spiritual leader, Father Mylonas of blessed memory, and step right into a multi-million dollar building project. But he did it with grace and good humor. The church thanks Father Peter for all that he has done. I feel certain that Father Mylonas would be proud of the work you have done.So here we are with plenty of hard work and sacrifice behind us. But look at where we are. Take a good look around this room. Admire what we have accomplished together. The family of St. Anthony has been without a kitchen and family room for quite some time. We have had no place to break bread, no place to dance, no place to teach and no place to learn. We have had no place for fellowship – but we are still together and, I believe, a stronger community for it.Your patience is to be commended, and it has been rewarded. We now have a beautiful community center where we can participate in all of the aspects of parish life for decades to come. And we should take the time to bask in what we have accomplished for our parish, but we should equally be proud of what we have accomplished for the greater Greek Orthodox community.”St. Anthony Greek Orthodox Church, 778 South Rosemead Boulevard, Pasadena, (626) 449-6943 or visit www.saint-anthonys.org.center_img Community News EVENTS & ENTERTAINMENT | FOOD & DRINK | THE ARTS | REAL ESTATE | HOME & GARDEN | WELLNESS | SOCIAL SCENE | GETAWAYS | PARENTS & KIDS Pasadena Will Allow Vaccinated People to Go Without Masks in Most Settings Starting on Tuesday Make a comment First Heatwave Expected Next Week Your email address will not be published. Required fields are marked * faithfernandez More » ShareTweetShare on Google+Pin on PinterestSend with WhatsApp,Virtual Schools PasadenaHomes Solve Community/Gov/Pub SafetyCitizen Service CenterPASADENA EVENTS & ACTIVITIES CALENDARClick here for Movie Showtimes More Cool Stuff Business Newslast_img read more

Adamas Pharmaceuticals Announces Pricing of Follow-on Public Offering

first_img WhatsApp Facebook TAGS  Facebook Twitter WhatsApp Previous article050319 OHS Socorro Baseball_14Next articleNUGGETS: Now Faith Digital AIM Web Support Adamas Pharmaceuticals Announces Pricing of Follow-on Public Offeringcenter_img EMERYVILLE, Calif.–(BUSINESS WIRE)–Feb 24, 2021– Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock at a price to the public of $4.40 per share. All of the shares in the offering are being sold by Adamas. The gross proceeds of the offering to Adamas, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $55.0 million, excluding any exercise of the underwriters’ option. Adamas has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of its common stock offered in the public offering. The offering is expected to close on March 1, 2021, subject to customary closing conditions. SVB Leerink and William Blair are joint bookrunning managers for the offering. JMP Securities is lead manager for the offering. The securities described above are being offered by Adamas pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”). The offering is being made only by means of a prospectus supplement and accompanying prospectus, which will be available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, from: SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808 7525, ext. 6105, or by email at [email protected]; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, telephone: 1-800-621-0687, or by email: [email protected] This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Adamas Pharmaceuticals, Inc. At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Adamas’ expectations regarding the completion of the public offering. These statements are subject to significant risks and uncertainties and actual results could differ materially from those projected. Adamas cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, the closing of the offering is subject to the satisfaction of customary closing conditions. Risks and uncertainties relating to Adamas and its business can be found in the “Risk Factors” section of Adamas’ Form 10-K for the year ended December 31, 2020, filed with the SEC on February 23, 2021, and in the preliminary prospectus supplement related to the public offering filed with the SEC on February 24, 2021. Adamas undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in Adamas’ expectations, except as required by law. Source: Adamas Pharmaceuticals, Inc. View source version on businesswire.com:https://www.businesswire.com/news/home/20210224006216/en/ CONTACT: Media: Sarah Mathieson Vice President, Corporate Communications 510-450-3528 [email protected] Investors: Peter Vozzo Managing Director Westwicke/ICR 443-213-0505 [email protected] KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH HOSPITALS HEALTH PHARMACEUTICAL SOURCE: Adamas Pharmaceuticals, Inc. Copyright Business Wire 2021. PUB: 02/24/2021 09:16 PM/DISC: 02/24/2021 09:16 PM http://www.businesswire.com/news/home/20210224006216/en Twitter By Digital AIM Web Support – February 24, 2021 Pinterest Local NewsBusiness Pinterestlast_img read more